Advances in medicine come from new ideas developed through clinical trials and research. At Renown Health, we conduct hundreds of clinical trials (also called research trials or research studies) in our ongoing effort to discover and deliver more effective treatments.
Our goal is to translate discoveries made in the laboratory to the patients who will benefit from them, and to do it as quickly as possible.
Select a category from the list below, and contact us at 775-982-5050 for a more thorough explanation of each study.
The objective of the RADIANCE-HTN study is to demonstrate the efficacy and verify the safety of the Paradise System in two distinct populations of hypertensive subjects. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication or despite the presence of a stabilized, single pill, triple, fixed dose antihypertensive medication regimen.
The purpose of this study is to evaluate the effect of Entresto compared to valsartan on cognitive function in patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The patients will be evaluated for three years assessing the memory, executive function, and attention.
To assess the treatment of omecamtiv mecarbil (OM) compared with placebo when added to the normal standard of care in Heart Failure patients. To analyze the reduction of Heart Failure hospitalization and improved symptoms in subjects with chronic Heart Failure with Reserved Ejection Fraction (HFrEF). Treatment goals are to improve symptoms, prolong survival and reduce hospital readmissions.
MobiusHD is an investigational implant designed to lower blood pressure through a minimally-invasive procedure. Once placed, the MobiusHD implant is designed to increase signals from the baroreceptors. As the brain receives these amplified signals, it perceives blood pressure to be higher than it actually is, thereby triggering the body’s natural process to reduce blood pressure.
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention.
The CardioMEMS HF System consists of a wireless, battery-less pressure sensor implanted into the pulmonary artery and an external electronics that powers and communicates with the sensor and transmits pulmonary artery pressure waveforms and measurements to a secure website for Investigator review and patient management.
To test the inflammatory hypothesis of atherothrombosis. Specifically, CIRT will evaluate whether LDM will reduce rates of myocardial infarction, stroke, or cardiovascular death among patients with a recent history of coronary artery disease and either type 2 diabetes or metabolic syndrome, conditions associated with an enhanced pro-inflammatory response.
To investigate the differences between patients that may influence the choice of anticoagulation medication that is selected for the prevention of stroke in AF patients, and to collect information on important health related events and anticoagulation treatments related to AF in a real-world setting and potential side effects of anticoagulant treatment (patients being treated in a doctor's office as opposed to research data gathered during a controlled research study).
The purpose of this study is to assess the effect of in-hospital initiation of acubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
To evaluate the effectiveness of an intervention with a mobile adherence platform, compared to physician- or nurse-guided standard of care, to improve medication adherence to rivaroxaban in subjects who have recently initiated treatment with rivaroxaban for stroke prevention in atrial fibrillation based on an assessment of the PDC of rivaroxaban treatment.
Acute chest pain is one of the most common presenting symptoms in emergency department (ED). Accurately identifying low risk patients who may be eligible for early discharge has significant impact on patient care and resource utilization. SVEAT is a scoring system that incorporates appropriate and precise clinical information to improve the capability to accurately identify low risk acute chest pain patients presenting to ED.
- Examine the prevalence of preadmission NOA use in patients who present with AIS or ICH;
- Describe and characterize diagnostic tests being used to assess level of anticoagulation when a patient presents with AIS or ICH on one of the NOA;
- Examine the utilization and safety profile of thrombolytic therapy in AIS patients on NOA as compared with those on warfarin;
- Document current practice patterns for the care of oral anticoagulant-related ICH and determine how treatment and clinical outcomes vary by NOA and warfarin therapy
As the largest healthcare system in northern Nevada and eastern California, and in partnership with the National Cancer Institute and the Nevada Cancer Research Foundation, we have access to dozens of open clinical trials.
We provide education and guidance to help patients make decisions about their care and treatment. Our specially trained research nurses will help you understand the process and explain what to expect with each visit. We are committed to bringing the highest quality of cancer care to you and your loved ones.
Purpose of this study is to evaluate clinical, humanistic and health economic burden of Respiratory Syncytial Virus (RSV) in infants born 29 to 35 Weeks Gestational Age (wGA) hospitalized for RSV at up to 12 months of age.
Part B of the study is randomized, double-blind, and placebo-controlled, designed to evaluate the efficacy, safety, serum concentration and immunogenicity of IM administration of REGN2222 in preterm infants for whom palivizumab is not recommended.
No trials found.